ATPA
5mg
| ≥98%
CSNpharm
CSNpharm
ATR-101 is a selective inhibitor of acyl coenzyme A:cholesterol acyltransferase (ACAT1), it is in clinical development for the treatment of adrenocortical carcinoma (ACC).
More Information
Supplier Page
CSNpharm
ATR-101 is a selective inhibitor of acyl coenzyme A:cholesterol acyltransferase (ACAT1), it is in clinical development for the treatment of adrenocortical carcinoma (ACC).
More Information
Supplier Page
CSNpharm
ATR-101 is a selective inhibitor of acyl coenzyme A:cholesterol acyltransferase (ACAT1), it is in clinical development for the treatment of adrenocortical carcinoma (ACC).
More Information
Supplier Page
CSNpharm
ATR-101 is a selective inhibitor of acyl coenzyme A:cholesterol acyltransferase (ACAT1), it is in clinical development for the treatment of adrenocortical carcinoma (ACC).
More Information
Supplier Page
CSNpharm
CSNpharm
CSNpharm
CSNpharm
Atractylone, a natural product isolated and purified from the roots of Atractylodes macrocephala, has inhibitory effects on mast cell-mediated allergic reactions, it regulates the degranulation of mast cell, proves its potential in the treatment of mast cell-mediated allergic reactions.
More Information
Supplier Page
CSNpharm
CSNpharm
CSNpharm
CSNpharm
CSNpharm
CSNpharm
CSNpharm
CSNpharm
CSNpharm
CSNpharm
CSNpharm
CSNpharm
Atraric acid, a natural product isolated and purified from the fruits of Vitis vinifera L., inhibits the invasiveness of LNCaP cells through extracellular matrix.
More Information
Supplier Page
CSNpharm
Atrasentan HCl is an endothelin receptor antagonist (IC50=0.0551 nM, ETA) being developed for the treatment of prostate cancer.
More Information
Supplier Page
CSNpharm
Atrasentan HCl is an endothelin receptor antagonist (IC50=0.0551 nM, ETA) being developed for the treatment of prostate cancer.
More Information
Supplier Page
CSNpharm
Atrasentan HCl is an endothelin receptor antagonist (IC50=0.0551 nM, ETA) being developed for the treatment of prostate cancer.
More Information
Supplier Page
CSNpharm
Atrasentan HCl is an endothelin receptor antagonist (IC50=0.0551 nM, ETA) being developed for the treatment of prostate cancer.
More Information
Supplier Page
CSNpharm
CSNpharm
CSNpharm
CSNpharm
CSNpharm
Auranofin is a proteasomal deubiquitinase inhibitor with inhibition of the proteasome-associated deubiquitinases (DUBs) UCHL5 and USP14 rather than 20S proteasome, which is required for Auranofin-induced cytotoxicity. It selectively inhibits tumor growth in vivo and induces cytotoxicity in cancer cells from acute myeloid leukemia patients and by blocking NF-κB activation, Auranofin can attenuats the cardiac hypertrophy.
More Information
Supplier Page
CSNpharm
Auranofin is a proteasomal deubiquitinase inhibitor with inhibition of the proteasome-associated deubiquitinases (DUBs) UCHL5 and USP14 rather than 20S proteasome, which is required for Auranofin-induced cytotoxicity. It selectively inhibits tumor growth in vivo and induces cytotoxicity in cancer cells from acute myeloid leukemia patients and by blocking NF-κB activation, Auranofin can attenuats the cardiac hypertrophy.
More Information
Supplier Page
CSNpharm
Auranofin is a proteasomal deubiquitinase inhibitor with inhibition of the proteasome-associated deubiquitinases (DUBs) UCHL5 and USP14 rather than 20S proteasome, which is required for Auranofin-induced cytotoxicity. It selectively inhibits tumor growth in vivo and induces cytotoxicity in cancer cells from acute myeloid leukemia patients and by blocking NF-κB activation, Auranofin can attenuats the cardiac hypertrophy.
More Information
Supplier Page
CSNpharm
GlucoAurantio-obtusin, a natural product isolated and purified from the seeds of Cassia obtusifolia L., possesses hypotensive and hypolipidemic effects.
More Information
Supplier Page
CSNpharm
GlucoAurantio-obtusin, a natural product isolated and purified from the seeds of Cassia obtusifolia L., possesses hypotensive and hypolipidemic effects.
More Information
Supplier Page
CSNpharm
GlucoAurantio-obtusin, a natural product isolated and purified from the seeds of Cassia obtusifolia L., possesses hypotensive and hypolipidemic effects.
More Information
Supplier Page
CSNpharm
Auraptene is a natural product isolated and purified from the peel of Poncirus trifoliata with anti-tumor and anti-oxidant activity. Auraptene-mediated activation of JNK may contribute to the production of Aβ by promoting γ-secretase activity.
More Information
Supplier Page
CSNpharm
Auraptene is a natural product isolated and purified from the peel of Poncirus trifoliata with anti-tumor and anti-oxidant activity. Auraptene-mediated activation of JNK may contribute to the production of Aβ by promoting γ-secretase activity.
More Information
Supplier Page
CSNpharm
Auraptene is a natural product isolated and purified from the peel of Poncirus trifoliata with anti-tumor and anti-oxidant activity. Auraptene-mediated activation of JNK may contribute to the production of Aβ by promoting γ-secretase activity.
More Information
Supplier Page
CSNpharm
Auraptene is a natural product isolated and purified from the peel of Poncirus trifoliata with anti-tumor and anti-oxidant activity. Auraptene-mediated activation of JNK may contribute to the production of Aβ by promoting γ-secretase activity.
More Information
Supplier Page
CSNpharm
CSNpharm
CSNpharm
Aurothioglucose is a well known active-site inhibitor of TrxR1, inhibited TrxR1 activity in HeLa cell cytosol but had no effect on the viability of the cells.
More Information
Supplier Page
CSNpharm
Aurothioglucose is a well known active-site inhibitor of TrxR1, inhibited TrxR1 activity in HeLa cell cytosol but had no effect on the viability of the cells.
More Information
Supplier Page
CSNpharm
Autophinib is an ATP-competitive inhibitor of the VPS34 with IC50 of 19 nM, also inhibitor of starvation- and Rapamycin-induced autophagy with IC50 of 40 and 90 nM respectively.
More Information
Supplier Page
CSNpharm
Autophinib is an ATP-competitive inhibitor of the VPS34 with IC50 of 19 nM, also inhibitor of starvation- and Rapamycin-induced autophagy with IC50 of 40 and 90 nM respectively.
More Information
Supplier Page
CSNpharm
Autophinib is an ATP-competitive inhibitor of the VPS34 with IC50 of 19 nM, also inhibitor of starvation- and Rapamycin-induced autophagy with IC50 of 40 and 90 nM respectively.
More Information
Supplier Page
CSNpharm
Autophinib is an ATP-competitive inhibitor of the VPS34 with IC50 of 19 nM, also inhibitor of starvation- and Rapamycin-induced autophagy with IC50 of 40 and 90 nM respectively.
More Information
Supplier Page
CSNpharm
Autophinib is an ATP-competitive inhibitor of the VPS34 with IC50 of 19 nM, also inhibitor of starvation- and Rapamycin-induced autophagy with IC50 of 40 and 90 nM respectively.
More Information
Supplier Page
CSNpharm
Auxinole is a potent auxin antagonist of TIR1/AFB receptors, binding TIR1 to block the formation of the TIR1-IAA-Aux/IAA complex and so inhibits auxin-responsive gene expression.
More Information
Supplier Page
CSNpharm
Auxinole is a potent auxin antagonist of TIR1/AFB receptors, binding TIR1 to block the formation of the TIR1-IAA-Aux/IAA complex and so inhibits auxin-responsive gene expression.
More Information
Supplier Page
